Cambareri Christine
University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania.
J Adv Pract Oncol. 2022 Apr;13(3):275-281. doi: 10.6004/jadpro.2022.13.3.19. Epub 2022 May 23.
During JADPRO Live Virtual 2021, Christine Cambareri, PharmD, BCPS, BCOP, CSP, briefed advanced practitioners on drugs and biologics that were approved for the treatment of solid tumors from late 2020 to late 2021, including their adverse event profiles. The trend of more oral dosage forms and the significant number of checkpoint inhibitors approved points towards changing treatment paradigms in the field.
在2021年JADPRO现场虚拟会议期间，药学博士、BCPS、BCOP、CSP克里斯汀·坎巴雷里向高级从业者介绍了2020年末至2021年末获批用于治疗实体瘤的药物和生物制剂，包括它们的不良事件概况。更多口服剂型的趋势以及大量获批的检查点抑制剂表明该领域的治疗模式正在发生变化。
